Dashboard
Manage Tickers

LEXXW Lexaria Bioscience Corp.

Nasdaq www.lexariabioscience.com


$ 0.04 $ 0.02 (94.48 %)    

Monday, 20-Oct-2025 15:57:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 610.88 $ -0.65 (-0.11 %)
DIA $ 470.39 $ 3.38 (0.72 %)
SPY $ 671.88 $ 0.38 (0.06 %)
TLT $ 92.06 $ 0.07 (0.08 %)
GLD $ 380.15 $ -6.49 (-1.68 %)
$ 0.0352
$ 0.02
$ 0.03 x 100
$ 0.05 x 4,000
-- - --
$ 0.02 - $ 1.31
95,833
na
18.44M
$ 1.34
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-14-2025 05-31-2025 10-Q
2 04-14-2025 02-28-2025 10-Q
3 01-10-2025 11-30-2024 10-Q
4 11-26-2024 08-31-2024 10-K
5 07-12-2024 05-31-2024 10-Q
6 04-09-2024 02-29-2024 10-Q
7 01-12-2024 11-30-2023 10-Q
8 11-20-2023 08-31-2023 10-K
9 07-14-2023 05-31-2023 10-Q
10 04-14-2023 02-28-2023 10-Q
11 01-17-2023 11-30-2022 10-Q
12 11-28-2022 08-31-2022 10-K
13 07-14-2022 05-31-2022 10-Q
14 04-11-2022 02-28-2022 10-Q
15 01-14-2022 11-30-2021 10-Q
16 11-27-2021 08-31-2021 10-K
17 07-15-2021 05-31-2021 10-Q
18 04-14-2021 02-28-2021 10-Q
19 01-14-2021 11-30-2020 10-Q
20 10-15-2020 08-31-2020 10-K
21 06-30-2020 05-31-2020 10-Q
22 04-03-2020 02-29-2020 10-Q
23 01-09-2020 11-30-2019 10-Q
24 11-14-2019 08-31-2019 10-K
25 07-08-2019 05-31-2019 10-Q
26 04-15-2019 02-28-2019 10-Q
27 01-11-2019 11-30-2018 10-Q
28 11-14-2018 08-31-2018 10-K
29 07-13-2018 05-31-2018 10-Q
30 04-12-2018 02-28-2018 10-Q
31 01-12-2018 11-30-2017 10-Q
32 11-27-2017 08-31-2017 10-K
33 07-14-2017 05-31-2017 10-Q
34 04-14-2017 02-28-2017 10-Q
35 01-13-2017 11-30-2016 10-Q
36 11-29-2016 08-31-2016 10-K
37 07-13-2016 05-31-2016 10-Q
38 04-13-2016 02-29-2016 10-Q
39 01-08-2016 11-30-2015 10-Q
40 11-27-2015 08-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Lexaria Bioscience Announces Results From ...
09/19/2025 15:22:17

Enhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and EfficacyLexaria Bioscience Corp. (NA...

Core News & Articles
Lexaria Bioscience's Contract Research Org...
08/14/2025 13:23:23

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d...

Core News & Articles
Lexaria Provides Partial 8-Week Interim Re...
07/28/2025 13:27:22

DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastroint...

Core News & Articles
Lexaria's DehydraTECH Targets Side Effects...
07/23/2025 13:29:54

The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted sid...

Core News & Articles
Lexaria Bioscience Receives Two New Patent...
06/23/2025 13:18:14

New patents received for the treatment of epilepsy and for the sublingual delivery of nicotineKELOWNA, BC / ACCESS Newswire / J...

Core News & Articles
Lexaria Bioscience Agrees With Single Inst...
04/25/2025 12:14:42

KELOWNA, BC / ACCESS Newswire / April 25, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or...

Core News & Articles
Lexaria Bioscience Issues Glucagon-like Pe...
04/23/2025 13:15:48

Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industryLexaria's technology could enhance pe...

Core News & Articles
Lexaria Bioscience Announces It Has Begun ...
12/19/2024 14:21:47

Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight lossKELOWNA, BC / ACCESSWIRE / December...

Core News & Articles
Lexaria Bioscience Says Liraglutide Proces...
12/09/2024 14:13:10

Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutideKELOWNA, BC ...

Core News & Articles
Lexaria Bioscience Provides Strategic Upda...
11/26/2024 14:25:36

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and moreGLP-1 drugs expected ...

Core News & Articles
Lexaria Bioscience Announces That It Has R...
10/22/2024 13:28:40

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groupsAccelerated rates of ...

Core News & Articles
Lexaria Appoints Michael Shankman As Chief...
10/01/2024 13:27:34

Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in...

Core News & Articles
Lexaria Receives Independent Review Board ...
09/27/2024 13:24:10

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral formatKELOWNA, BC / ACCESSWIRE / S...

Core News & Articles
Lexaria Bioscience Announces Tolerability ...
08/29/2024 13:36:37

Absorption improvements appear to continue with DehydraTECH-processed Rybelsus® vs. Rybelsus® tablets even under "fed" ...

Core News & Articles
Lexaria Preparing For Strategic Growth, Ex...
07/16/2024 13:30:09

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d...

Core News & Articles
Lexaria Receives 3 New Patents For Antivir...
07/08/2024 13:20:09

Lexaria currently holding 46 granted patents worldwideKELOWNA, BC / ACCESSWIRE / July 8, 2024 / Lexaria Bioscience Corp. (NASDA...

Core News & Articles
Lexaria Awards Contract To A CRO To Perfor...
05/23/2024 14:56:55

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral formatKELOWNA, BC / ACCESSWIRE / M...

Core News & Articles
Lexaria Announces New Research Program To ...
05/06/2024 13:08:30

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d...

Core News & Articles
Lexaria To Receive $4.7M Gross Proceeds In...
04/30/2024 19:53:35

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d...

Core News & Articles
Lexaria Receives Ethics Review Board Appro...
04/16/2024 13:17:08

Human Pilot Study #2 (GLP-1-H24-2) ApprovedKELOWNA, BC / ACCESSWIRE / April 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(N...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION